NCT04425538View on ClinicalTrials.gov

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
COVID-19
Interventions
DRUG

Infliximab

Either infliximab or infliximab-abda will be used at the discretion of the investigator

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Tufts Medical Center

OTHER

NCT04425538 - A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). | Biotech Hunter | Biotech Hunter